ALKERMES | ALKS - Cost Of Sales


ALKERMES reported $120.7M in Cost of Sales for its fiscal quarter ending in June of 2026.





Cost Of Sales Change Date
AbbVie USD 4.29B 73M Jun/2026
Acadia Pharmaceuticals USD 28.32M 3.52M Jun/2026
ALKERMES USD 120.7M 47.44M Jun/2026
Amgen USD 1.87B 271M Jun/2026
Biogen USD 945.1M 147.6M Jun/2026
BioMarin Pharmaceutical USD 276.29M 76.8M Jun/2026
Bristol-Myers Squibb USD 7.89B 4.03B Jun/2026
Coherus Biosciences USD 4.04M 324K Dec/2025
Eli Lilly USD 3.27B 309M Jun/2026
Gilead Sciences USD 1000M 445M Jun/2026
Heron Therapeutics USD 11.12M 795K Dec/2025
Ionis Pharmaceuticals USD 2.74M 261K Jun/2026
J&J USD 8B 67M Jun/2026
Merck USD 3.14B 200M Jun/2026
Minerva Neurosciences 386K 31K Jun/2024
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neurocrine Biosciences USD 39.4M 25.6M Jun/2026
Otsuka Holdings JPY 191.82B 17.73B Jun/2026
Pfizer USD 4.09B 498M Jun/2026
Regeneron Pharmaceuticals USD 576.5M 92.9M Jun/2026
Vertex Pharmaceuticals USD 489.2M 96.4M Jun/2026